NADAC acquisition cost data for TYBLUME 0.1-0.02 MG CHEW TAB. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00642747101 | $0.7466 | 2022-12-21 | Rx |
| 00642747101 | $0.7466 | 2022-12-21 | Rx |
Generic: Levonorgestrel/Ethin.Estradiol | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2022 | $968.60 | 24 | N/A | $0.8236 |
| 2023 | $2.6K | 75 | 32 | $0.8087 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $651.73 | 18 | N/A |
| New York | $541.90 | 11 | N/A |
| Alabama | $334.18 | 14 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.